» Articles » PMID: 36515811

Liraglutide Provides Cardioprotection Through the Recovery of Mitochondrial Dysfunction and Oxidative Stress in Aging Hearts

Overview
Specialties Biochemistry
Physiology
Date 2022 Dec 14
PMID 36515811
Authors
Affiliations
Soon will be listed here.
Abstract

Glucagon-like peptide-1 receptor (GLP-1R) agonists improve cardiovascular dysfunction via the pleiotropic effects behind their receptor action. However, it is unknown whether they have a cardioprotective action in the hearts of the elderly. Therefore, we examined the effects of GLP-1R agonist liraglutide treatment (LG, 4 weeks) on the systemic parameters of aged rats (24-month-old) compared to those of adult rats (6-month-old) such as electrocardiograms (ECGs) and systolic and diastolic blood pressure (SBP and DBP). At the cellular level, the action potential (AP) parameters, ionic currents, and Ca regulation were examined in freshly isolated ventricular cardiomyocytes. The LG treatment of aged rats significantly ameliorated the prolongation of QRS duration and increased both SBP and DBP together with recovery in plasma oxidant and antioxidant statuses. The prolonged AP durations and depolarized membrane potentials of the isolated cardiomyocytes from the aged rats were normalized via recoveries in K channel currents with LG treatment. The alterations in Ca regulation including leaky-ryanodine receptors (RyR2) could be also ameliorated via recoveries in Na/Ca exchanger currents with this treatment. A direct LG treatment of isolated aged rat cardiomyocytes could recover the depolarized mitochondrial membrane potential, the increase in both reactive oxygen and nitrogen species (ROS and RNS), and the cytosolic Na level, although the Na channel currents were not affected by aging. Interestingly, LG treatment of aged rat cardiomyocytes provided a significant inhibition of activated sodium-glucose co-transporter-2 (SGLT2) and recoveries in the depressed insulin receptor substrate 1 (IRS1) and increased protein kinase G (PKG). The recovery in the ratio of phospho-endothelial nitric oxide (pNOS3) level to NOS3 protein level in LG-treated cardiomyocytes implies the involvement of LG-associated inhibition of oxidative stress-induced injury via IRS1-eNOS-PKG pathway in the aging heart. Overall, our data, for the first time, provide important information on the direct cardioprotective effects of GLP-1R agonism with LG in the hearts of aged rats through an examination of recoveries in mitochondrial dysfunction, and both levels of ROS and RNS in left ventricular cardiomyocytes.

Citing Articles

The role of glucagon-like peptide-1 receptor (GLP-1R) agonists in enhancing endothelial function: a potential avenue for improving heart failure with preserved ejection fraction (HFpEF).

Hullon D, Subeh G, Volkova Y, Janiec K, Trach A, Mnevets R Cardiovasc Diabetol. 2025; 24(1):70.

PMID: 39920668 PMC: 11806760. DOI: 10.1186/s12933-025-02607-w.


Acute GLP-1 Agonism Induces Arrhythmogenic Electrical Activity in Aged Mice Heart Through Impaired Cellular Na+ and Ca2+ Handlings: The Role of CK2 Hyperphosphorylation.

Olgar Y, Durak A, Turan B Anatol J Cardiol. 2024; .

PMID: 39655941 PMC: 11793800. DOI: 10.14744/AnatolJCardiol.2024.4719.


GLP-1R activation attenuates the progression of pulmonary fibrosis via disrupting NLRP3 inflammasome/PFKFB3-driven glycolysis interaction and histone lactylation.

Liu C, Zhang Q, Zhou H, Jin L, Liu C, Yang M J Transl Med. 2024; 22(1):954.

PMID: 39434134 PMC: 11492558. DOI: 10.1186/s12967-024-05753-z.


Beyond weight loss: the potential of glucagon-like peptide-1 receptor agonists for treating heart failure with preserved ejection fraction.

Wang T, Yang Q, Cheng X, Ding J, Hu P Heart Fail Rev. 2024; 30(1):17-38.

PMID: 39269643 DOI: 10.1007/s10741-024-10438-2.


GLP-1 receptor agonists and myocardial metabolism in atrial fibrillation.

Zhong J, Chen H, Liu Q, Zhou S, Liu Z, Xiao Y J Pharm Anal. 2024; 14(5):100917.

PMID: 38799233 PMC: 11127228. DOI: 10.1016/j.jpha.2023.12.007.


References
1.
Ang R, Mastitskaya S, Hosford P, Basalay M, Specterman M, Aziz Q . Modulation of Cardiac Ventricular Excitability by GLP-1 (Glucagon-Like Peptide-1). Circ Arrhythm Electrophysiol. 2018; 11(10):e006740. PMC: 6553567. DOI: 10.1161/CIRCEP.118.006740. View

2.
Bai X, Hao J, Zheng R, Yan C, Wang J, Yang C . Glucagon-Like Peptide-1 Analog Liraglutide Attenuates Pressure-Overload Induced Cardiac Hypertrophy and Apoptosis through Activating ATP Sensitive Potassium Channels. Cardiovasc Drugs Ther. 2020; 35(1):87-101. DOI: 10.1007/s10557-020-07088-5. View

3.
Billur D, Tuncay E, Okatan E, Olgar Y, Durak A, Degirmenci S . Interplay Between Cytosolic Free Zn and Mitochondrion Morphological Changes in Rat Ventricular Cardiomyocytes. Biol Trace Elem Res. 2016; 174(1):177-188. DOI: 10.1007/s12011-016-0704-5. View

4.
Boudina S . Cardiac aging and insulin resistance: could insulin/insulin-like growth factor (IGF) signaling be used as a therapeutic target?. Curr Pharm Des. 2013; 19(32):5684-94. PMC: 3883087. DOI: 10.2174/1381612811319320004. View

5.
Brand C, Galsgaard E, Tornehave D, Romer J, Gotfredsen C, Wassermann K . Synergistic effect of the human GLP-1 analogue liraglutide and a dual PPARalpha/gamma agonist on glycaemic control in Zucker diabetic fatty rats. Diabetes Obes Metab. 2009; 11(8):795-803. DOI: 10.1111/j.1463-1326.2009.01049.x. View